KnowTheStock
Log inCreate free account

CorMedix Inc

CRMD
Pharmaceutical Preparation Manufacturing · NASDAQ
$7.64last close · market cap 706.54 Million
Compare with…
48.1SCORE / 100
Our verdictHOLDModerate Growth and ImprovingQtr Ending 2026-06-30 · trend positive

Why Hold

Balance sheet is strong; cash flow is moderate; income statement is weak.

Next earnings: 2026-11-11, EPS Forecast: ($0.05)

What is strong
  • Revenue Growth is 280.5%
  • Operating Income Growth is 340.08%
  • Net Income Growth is 265.86%
  • Earnings Per Share (EPS) Growth is 181.58%
  • Net Margin is 40.49%
  • Current Asset to Current Liability Ratio is 2.56
  • Debt Ratio is 0.49
  • Current Debt to Net Income Ratio is 0.0
  • Total Debt to Total Assets Ratio is 0.0
  • Cash from Operations Growth is 733.59%
  • Capital Expenditure is Low
  • Net Increase in Cash is Positive

What changed

Score by quarter

Upgraded from Sell to Hold in the Mar 2026 quarter: 29.5 → 47.3 (+17.8). This quarter: +0.8.

20304050Jun 2020Jun 2026

What the score is made of

Income statement37.8 +0.0
Balance sheet71.5 +0.0
Cash flow40.5 +5.1

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)462.25 Million280.50 % growth
EPS2.14181.58 % growth
Profit margin40.49 %Profit per $1 of sales
P-E ratio—Not available
Market cap706.54 MillionShares × price
Debt-equity ratio—Not available
Dividend0.00Per share, annual
Next earnings2026-11-11EPS forecast ($0.05)
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About CorMedix Inc

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.

CEO
Khoso Baluch
Employees
54
Sector
Manufacturing
Exchange
NASDAQ
cormedix.com

Similar stocks

Loading…